NasdaqGS - Nasdaq Real Time Price USD

ORIC Pharmaceuticals, Inc. (ORIC)

Compare

10.36

+0.36

(+3.60%)

At close: September 26 at 4:00 PM EDT

10.36

0.00

(0.00%)

After hours: September 26 at 4:20 PM EDT

ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) stands against the other cancer stocks. Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one […]

Insider Monkey 12 days ago

ORIC
+3.60%
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted a total of 173,200 non-qualified stock options and 28,900 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2024. These inducement

GlobeNewswire 20 days ago

ORIC
+3.60%
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference – Participating in a fireside chat on Thursday, September 5, 2024, at 8:00 a.m. ET Baird 2024 Global Healthcare Conference

GlobeNewswire last month

ORIC
+3.60%
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combination with NUBEQA® and in combination with ERLEADA® Expanded leadership team with the appointment of industry veteran Keith Lui as Senior Vice President of Commercial and Medical Affairs Cash an

GlobeNewswire last month

ORIC
+3.60%
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs. “We are thrilled to welcome Keith to the ORIC leadership team,” said Jacob M. Chacko, M.D., president and chief executive officer. “Keith’s exceptional multi

GlobeNewswire last month

ORIC
+3.60%
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.

Zacks 2 months ago

ORIC
+3.60%
BAYN.DE

JNJ
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic r

GlobeNewswire 2 months ago

ORIC
+3.60%
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. “I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a

GlobeNewswire 2 months ago

ORIC
+3.60%
Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?

We recently compiled a list of the 10 Most Shorted Stocks That Are Loved by Analysts. In this article, we are going to take a look at where ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) stands against the other shorted stocks that are loved by analysts. Short selling is one of the more controversial ways of making money […]

Insider Monkey 2 months ago

ORIC
+3.60%
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 4 months ago

ORIC
+3.60%
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-class profile with strong pharmacokinetic, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer Presented updat

GlobeNewswire 4 months ago

ORIC
+3.60%
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-naïve EGFR exon 20 NSCLC Expect to report updated Phase 1b data in the first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC

GlobeNewswire 5 months ago

ORIC
+3.60%
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors Preclinical synergy data in prostate cancer models reinforces the promise of ORIC-944 as a potential best-in-class treatment for combinations with AR inhibitors First data presentation on ORIC-613, a potential first- and best-in-class development candidate selectively inhibiti

GlobeNewswire 5 months ago

ORIC
+3.60%
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%

The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 39.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 5 months ago

ORIC
+3.60%
ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results

Advances in Clinical Programs and Strengthened Cash Position Highlighted

GuruFocus.com 6 months ago

ORIC
+3.60%
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate cancer expected in first half of 2024 and program update expected in mid-2024 Initiation of multiple dose expansion cohorts for ORIC-114 in patients with mutated NSCLC expected in first half of 2024 and updated

GlobeNewswire 6 months ago

ORIC
+3.60%
ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares

Jacob Chacko, the President and Chief Executive Officer of ORIC Pharmaceuticals Inc (NASDAQ:ORIC), has sold 40,000 shares of the company on March 6, 2024, according to a recent SEC Filing.

GuruFocus.com 6 months ago

ORIC
+3.60%
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will present a company overview at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 a.m. ET. A live webcast of the presentation will be available through the investor section of the company’s

GlobeNewswire 6 months ago

ORIC
+3.60%
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts have been accepted for presentation, including two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking pla

GlobeNewswire 6 months ago

ORIC
+3.60%
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 3:00 p.m. ET. A live webcast of the discussion will be available through the investor section of the company’s web

GlobeNewswire 7 months ago

ORIC
+3.60%

Performance Overview

Return	ORIC	S&P 500
YTD	+12.61%	+20.45%
1-Year	+37.04%	+32.46%
3-Year	-56.36%	+28.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ORIC Pharmaceuticals, Inc. (ORIC)

ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%

ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

Performance Overview